Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples

Bioanalysis

Volumn 3, Issue 10, 2011, Pages 1093-1097

  Ter Heine, Rob ^a   Mulder, Jan W ^a   Van Gorp, Eric C M ^a   Wagenaar, Jiri F P ^a   Beijnen, Jos H ^a   Huitema, Alwin D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR;

ADULT; ARTICLE; BLOOD SAMPLING; BLOOD STORAGE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXPOSURE; DRUG MONITORING; HEMATOCRIT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; LIQUID CHROMATOGRAPHY; MALE; TANDEM MASS SPECTROMETRY; TREATMENT DURATION;

BLOOD SPECIMEN COLLECTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PYRIDAZINES; PYRROLIDINONES; RITONAVIR; SULFONAMIDES;

EID: 79956205458     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.72     Document Type: Article

References (17)

1. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370(9581), 39-48 (2007). (Pubitemid 47017467)
2. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 370(9581), 29-38 (2007). (Pubitemid 47017466)
3. Scholler-Gyure M, Kakuda TN, Sekar V, et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir. Ther. 12(5), 789-796 (2007). (Pubitemid 47235493)
4. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N. Engl. J. Med. 359(4), 339-354 (2008).
5. Edelbroek PM, van der Heijden J, Stolk LM. Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther. Drug Monit. 31(3), 327-336 (2009).
6. Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative analysis of small molecules. Biomed. Chromatogr. 24(1), 49-65 (2010).
7. Ter Heine R, Rosing H, van Gorp EC, et al. Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 867(2), 205-212 (2008).
8. Ter Heine R, Hillebrand MJ, Rosing H, et al. Quantification of the HIV-integrase inhibitor raltegravir and detection of its main metabolite in human plasma, dried blood spots and peripheral blood mononuclear cell lysate by means of high-performance liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 49(2), 451-458 (2009).
9. Ter Heine R, Rosing H, van Gorp EC, Mulder JW, Beijnen JH, Huitema AD. Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry. J. Pharm. Biomed. Anal. 49(2), 393-400 (2009).
10. Koal T, Burhenne H, Romling R, Svoboda M, Resch K, Kaever V. Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/ tandem mass spectrometry. Rapid Commun. Mass Spectrom. 19(21), 2995-3001 (2005). (Pubitemid 41540724)
11. Malm M, Romsing S, Obua C, Bergqvist Y. Determination of lamivudine, zidovudine, and nevirapine in capillary blood sampled on filter paper by LC. J. Chromatogr. Sci. 47(10), 855-862 (2009).
12. Ter Heine R, Alderden-Los CG, Rosing H, et al. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 21(15), 2505-2514 (2007). (Pubitemid 47203278)
13. Knudsen R, Richmond JY, Slazyk W, Hannon H. Guidelines from the centers for disease control and prevention for the shipment of dried blood spot specimens. Infant Screening 16, 1-3 (1993).
14. Emmons G, Rowland M. Pharmacokinetic considerations as to when to use dried blood spot sampling. Bioanalysis 2(11), 1791-1796 (2010).
15. Rowland M, Emmons GT. Use of dried blood spots in drug development: pharmacokinetic considerations. AAPS J. 12(3), 290-293 (2010).
16. Ter Heine R, Mulder JW, van Gorp EC, Wagenaar JF, Beijnen JH, Huitema AD. Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pretreated HIV-infected patients. Br. J. Clin. Pharmacol. 69(5), 475-483 (2010).
17. US Department of Health and Human Services Food and Drug Administration. Guidance for Industry Bioanalytical Method Validation (2001). www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm070107.pdf